Latest Financial Position News

Argosy Minerals has reported significant progress on its flagship Rincon Lithium Project, including an upgraded mineral resource estimate and advancing engineering and feasibility studies toward a 12,000tpa lithium carbonate operation.

Argosy Minerals Limited reported a net cash outflow in its December 2024 quarter, driven by exploration and evaluation expenses, ending with nearly $6 million in cash reserves.

Brockman Mining Limited's latest quarterly report reveals steady progress on the Marillana Project, underpinned by joint ventures with Mineral Resources and Hancock Prospecting, alongside key infrastructure developments at Port Hedland.

Bryah Resources Limited reported steady progress in its Bryah Basin manganese and copper-gold projects during the December 2024 quarter, while facing a notable decline in cash reserves and signaling plans for capital raising.

SIV Capital Limited reported a negative operating cash flow for Q2 FY25 and remains suspended from ASX trading due to compliance issues, while actively exploring acquisition opportunities.

MEC Resources has moved to place remaining shortfall shares and options following its recent entitlement offer, signaling a continued push to strengthen its capital base.

Oneview Healthcare reported a robust Q4 2024 cash flow update, bolstered by a significant equity raise and expanding partnerships, positioning the company for accelerated growth in 2025.

VDM Group Limited faces a complex ownership dispute over its Angolan projects, leading to halted exploration and a prolonged ASX trading suspension. Meanwhile, the company is actively pursuing new critical minerals opportunities in Australia to revive its operations.

ENRG Elements Limited reported a $586,000 net cash outflow for the December quarter, offset by a $2.02 million equity raise, boosting its cash reserves to $2.52 million.

Bod Science Limited reports a modest net cash inflow of $51,000 for Q2 FY2025, supported by increased customer receipts and intellectual property sales, while navigating a complex Deed of Company Arrangement and pending acquisition.

Alterity Therapeutics is poised to release topline data from its pivotal ATH434-201 Phase 2 trial in early-stage Multiple System Atrophy by February 2025, while managing a cash balance of A$4.54 million amid ongoing research expenses.

Gathid Ltd reports a strong quarter with a 92% year-on-year increase in Annual Recurring Revenue, new customer wins, and industry recognition, despite ongoing challenges in finalising the sale of its physical security business.